Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis

Company Overview

Ayala Pharmaceuticals is a clinical-stage biotechnology company focused on the development of innovative immunotherapies for cancer. The company’s core technology leverages a proprietary attenuated Listeria monocytogenes–based platform to deliver tumor-associated antigens directly to antigen-presenting cells, stimulating potent T-cell responses. By harnessing the body’s own immune system, Ayala aims to achieve durable anti-tumor activity while maintaining a favorable safety profile.

The company’s pipeline comprises several lead candidates targeting a variety of solid tumors. Among these is ADXS-HPV, an immunotherapy designed to treat human papillomavirus–associated cervical cancer, which has advanced into late-stage clinical trials. Ayala is also developing ADXS-NEO, a personalized neoantigen therapy tailored to individual patient tumor profiles, and ADXS-PSA for prostate cancer. These programs reflect the company’s commitment to addressing both virus-driven and mutation-driven malignancies.

Founded in the late 2000s under the name Advaxis, the company rebranded as Ayala Pharmaceuticals to underscore its evolution and expanded therapeutic focus. Headquartered in Princeton, New Jersey, Ayala conducts research and clinical operations across the United States and collaborates with academic and research institutions to advance its immunotherapy candidates. The company’s strategic alliances aim to accelerate clinical development and broaden access to its novel therapies.

Ayala’s leadership team brings together seasoned executives and scientific experts in oncology, immunology, and biopharmaceutical development. The company remains dedicated to translating its Listeria-based platform into meaningful treatments for patients with hard-to-treat cancers, leveraging its expertise to address unmet medical needs in the global oncology community.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.03 to $0.15
• 52-Week Range: $0.03 to $0.80
• Volume: 1,200 shs
• Average Volume: 4,032 shs
• Market Capitalization: $1.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ADXS Stock Analysis - Frequently Asked Questions

How have ADXS shares performed this year?

Ayala Pharmaceuticals' stock was trading at $0.0270 at the beginning of the year. Since then, ADXS shares have increased by 23.3% and is now trading at $0.0333.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) issued its earnings results on Thursday, September, 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The company had revenue of $0.25 million for the quarter.

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Acasti Pharma (ACST), Bristol Myers Squibb (BMY) and Matinas Biopharma (MTNB).

Company Calendar

• Last Earnings: 9/09/2021
• Today: 10/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADXS
• CIK: 1100397
• Web: www.ayalapharma.com
• Phone: 609-452-9813
• Fax: 609-452-9818
• Employees: 20
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.24 million
• Price / Sales: 0.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.06) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 42,633,000
• Free Float: 42,364,000
• Market Cap: $1.42 million
• Optionable: Not Optionable
• Beta: 1.22